<DOC>
	<DOCNO>NCT00007904</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together filgrastim radiation therapy work treat patient stage II stage IIIA breast cancer .</brief_summary>
	<brief_title>Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility administer adjuvant paclitaxel , dose-intensive cyclophosphamide , filgrastim ( G-CSF ) , follow doxorubicin radiotherapy patient stage II IIIA breast cancer involve &gt; 4 lymph node . - Determine incidence febrile neutropenia patient first course therapy . - Compare incidence febrile neutropenia duration neutropenia patient treat regimen see patient treat protocol CWRU-4194 . - Determine disease-free overall survival patient treat regimen . - Evaluate quality life patient . - Correlate HER-2/neu overexpression disease-free overall survival patient . OUTLINE : Patients receive paclitaxel IV continuously cyclophosphamide IV 2 hour day 1-3 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 5 continue day 14 blood count recover . Treatment repeat every 21 day 3 course . Patients receive doxorubicin IV day 1 G-CSF SC day 2-11 every 21 day 4 course . Patients hormone receptor positive disease also receive oral tamoxifen daily 5 year begin completion chemotherapy . Beginning 3-6 week completion chemotherapy , patient receive radiotherapy 5 day week 6-7 week . Quality life assess day 1 4 first course chemotherapy , day 1 second course , last day final course , 6 month completion treatment . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II IIIA breast cancer At least 5 axillary lymph nod No T4 N3 disease No distant metastases CT scan chest , abdomen , pelvis ; bone scan ; bone marrow evaluation No 8 week since prior lumpectomy mastectomy axillary node dissection Negative surgical margin Hormone receptor status : Hormone receptor status know PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No poorly control ischemic heart disease congestive heart failure Pulmonary : No severe chronic obstructive restrictive pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe diabetes mellitus No severe concurrent medical psychiatric illness would preclude study participation No malignancy within past 5 year except curatively treat ductal carcinoma situ , lobular carcinoma situ , breast cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>